News
Shares of US clinical-stage biotech Apogee Therapeutics closed down 17.3% at $39.24 yesterday, despite announcing positive 16 ...
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...
Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...
Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
The once-monthly drug is still under study but could provide added convenience and another option for patients.
Estimates for Eli Lilly’s 2025 earnings have declined from $23.06 to $21.95 per share in the past 60 days, and estimates for 2026 earnings have declined from $31.15 to $30.91 over the same ...
13d
Stocktwits on MSNEli Lilly’s Newest Obesity Drug Candidate Stirs Wall Street Buzz, But Not Everyone’s SoldEli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...
13d
MedPage Today on MSNADA Roundup: Weight-Loss Studies Take Center StageBelow are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results